BR112023018842A2 - Liberação de fármaco seletiva de conjugados - Google Patents
Liberação de fármaco seletiva de conjugadosInfo
- Publication number
- BR112023018842A2 BR112023018842A2 BR112023018842A BR112023018842A BR112023018842A2 BR 112023018842 A2 BR112023018842 A2 BR 112023018842A2 BR 112023018842 A BR112023018842 A BR 112023018842A BR 112023018842 A BR112023018842 A BR 112023018842A BR 112023018842 A2 BR112023018842 A2 BR 112023018842A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugates
- drug release
- amino acid
- acid sequence
- biologically active
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000005600 Cathepsins Human genes 0.000 abstract 1
- 108010084457 Cathepsins Proteins 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
liberação de fármaco seletiva de conjugados internalizados de compostos biologicamente ativos. a invenção se refere a conjugados de compostos biologicamente ativos, em que tal conjugado é constituído por uma sequência de aminoácidos contendo um tripeptídeo que confere clivagem seletiva pelo homogeneizado de tecido tumoral para liberação de fármaco livre e/ou melhorar a biodistribuição no tecido tumoral em comparação com homogeneizado de tecido normal da mesma espécie, em que o tecido normal é o local de um evento adverso associado à administração a um sujeito humano em necessidade de uma quantidade terapeuticamente eficaz de um conjugado de comparação, cuja sequência de aminoácidos é um dipeptídeo conhecido por ser seletivamente clivável por catepsina b.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163163017P | 2021-03-18 | 2021-03-18 | |
US202163163028P | 2021-03-18 | 2021-03-18 | |
US202163163008P | 2021-03-18 | 2021-03-18 | |
PCT/US2022/071211 WO2022198232A1 (en) | 2021-03-18 | 2022-03-17 | Selective drug release from internalized conjugates of biologically active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023018842A2 true BR112023018842A2 (pt) | 2023-12-26 |
Family
ID=81327354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023018842A BR112023018842A2 (pt) | 2021-03-18 | 2022-03-17 | Liberação de fármaco seletiva de conjugados |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240207427A1 (pt) |
EP (1) | EP4308171A1 (pt) |
JP (1) | JP2024511360A (pt) |
KR (1) | KR20230158006A (pt) |
AU (1) | AU2022237791A1 (pt) |
BR (1) | BR112023018842A2 (pt) |
CA (1) | CA3213625A1 (pt) |
IL (1) | IL305886A (pt) |
MX (1) | MX2023010819A (pt) |
TW (1) | TW202300179A (pt) |
WO (1) | WO2022198232A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2023178289A2 (en) * | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023216956A1 (zh) * | 2022-05-13 | 2023-11-16 | 四川科伦博泰生物医药股份有限公司 | 喜树碱类化合物及其制备方法和应用 |
WO2024078586A1 (en) * | 2022-10-14 | 2024-04-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugate binding to human ptk7 and method for preparation and use thereof |
WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
WO2024109840A1 (zh) * | 2022-11-22 | 2024-05-30 | 康诺亚生物医药科技(成都)有限公司 | 稠环类化合物及其偶联物和用途 |
KR20240077919A (ko) * | 2022-11-25 | 2024-06-03 | 주식회사 레고켐 바이오사이언스 | 링커-약물 접합체 제조방법 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス,インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
CA2841741C (en) | 2003-11-06 | 2020-01-07 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス, インコーポレイテッド | フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物 |
PL3248613T3 (pl) | 2005-07-18 | 2022-04-19 | Seagen Inc. | Koniugaty β-glukuronid-linker-lek |
PL1813614T3 (pl) | 2006-01-25 | 2012-03-30 | Sanofi Sa | Środki cytotoksyczne zawierające nowe pochodne tomaymycyny |
DK2842575T3 (da) | 2008-03-18 | 2017-11-27 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
IL295601B1 (en) | 2009-02-05 | 2024-07-01 | Immunogen Inc | History of benzodiazepines and processes for their preparation |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
BR112013020540B1 (pt) | 2011-02-15 | 2020-12-29 | Immunogen, Inc | métodos para preparação de conjugados compreendendo agente de ligação à célula conjugado a composto citotóxico com grupo ligante |
NZ717668A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
CN106170303B (zh) * | 2014-11-20 | 2019-10-25 | 法罗斯根有限公司 | 通过半胱天冬酶激活的前体药物 |
WO2019091384A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
EP4031186A1 (en) * | 2019-09-19 | 2022-07-27 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2021067820A1 (en) * | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
-
2022
- 2022-03-17 IL IL305886A patent/IL305886A/en unknown
- 2022-03-17 KR KR1020237034419A patent/KR20230158006A/ko unknown
- 2022-03-17 JP JP2023557043A patent/JP2024511360A/ja active Pending
- 2022-03-17 CA CA3213625A patent/CA3213625A1/en active Pending
- 2022-03-17 BR BR112023018842A patent/BR112023018842A2/pt unknown
- 2022-03-17 WO PCT/US2022/071211 patent/WO2022198232A1/en active Application Filing
- 2022-03-17 AU AU2022237791A patent/AU2022237791A1/en active Pending
- 2022-03-17 TW TW111109956A patent/TW202300179A/zh unknown
- 2022-03-17 EP EP22715943.1A patent/EP4308171A1/en active Pending
- 2022-03-17 MX MX2023010819A patent/MX2023010819A/es unknown
-
2023
- 2023-09-14 US US18/467,633 patent/US20240207427A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230158006A (ko) | 2023-11-17 |
EP4308171A1 (en) | 2024-01-24 |
MX2023010819A (es) | 2023-09-28 |
WO2022198232A1 (en) | 2022-09-22 |
TW202300179A (zh) | 2023-01-01 |
US20240207427A1 (en) | 2024-06-27 |
JP2024511360A (ja) | 2024-03-13 |
CA3213625A1 (en) | 2022-09-22 |
IL305886A (en) | 2023-11-01 |
AU2022237791A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023018842A2 (pt) | Liberação de fármaco seletiva de conjugados | |
BR112022004863A2 (pt) | Composição conjugado de ligante fármaco, compostos conjugado de ligante-fármaco e conector de fármaco, e, formulação farmaceuticamente aceitável | |
BR112023018676A2 (pt) | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco | |
BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
CY1113948T1 (el) | Θεραπευτικα δραστικα αλφα-msh αναλογα | |
EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
AR032556A1 (es) | Medicamento de accion inmediata para el tratamiento de la disfuncion sexual | |
ES2724932T3 (es) | Péptidos neuroprotectores | |
DK1079807T3 (da) | Anvendelse af præparater til tilförsel af antiseptiske midler og/eller midler, som fremmer heling af sår, til de nedre luftveje | |
BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
ES2193159T3 (es) | Una formulacion de factor de coagulacion viii. | |
BRPI0414428A (pt) | composições farmacêuticas | |
BRPI0415713A (pt) | mio-inositol hexafosfato para uso tópico | |
AR012256A1 (es) | Procedimiento para el tratamiento de la resistencia a la insulina en un mamifero, composiciones farmaceuticas, procedimiento para aumentar los nivelesde hormona de crecimiento endogena, procedimiento para el tratamiento o prevencion de la insuficiencia cardiaca congestiva, obesidad o debilidad | |
ES2585253T3 (es) | Composiciones para prevenir la pérdida de cabello o para estimular el crecimiento del cabello | |
BR0207510A (pt) | Conjugados de peg de hgf-nk4 | |
UY27378A1 (es) | Composición farmacéutica | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
BR112021026815A2 (pt) | Ligantes hidrofílicos para conjugados de peptídeo multivalentes | |
BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
BR0316523A (pt) | Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente | |
AR002049A1 (es) | Una composicion farmaceutica para la administracion oral de agentes activos que tienen baja solubilidad en agua y el procedimiento para prepararla | |
BR112019009511A2 (pt) | polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento. | |
BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 |